Organizational changes to support the development of retina programs at Ocular Therapeutix

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Ocular Therapeutix is ​​making changes to its management team, according to a press release.

Peter K. Kaiser, MD, will join the company in the newly created role of Chief Medical Advisor, Retina. He will be responsible for advising on clinical development strategies for the company’s retinal programs, including OTX-TKI, which is in Phase 1 development for the treatment of wet age-related macular degeneration and other diseases. retinal. He will also continue to serve as Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine and the Cole Eye Institute.

“The company’s lead program, OTX-TKI, has already demonstrated compelling results with a promising safety profile, preliminary biological activity signal and durability that could change the standard of care for patients with wet AMD. “, Kaiser said in the statement. “I think the same potential exists for applying the company’s hydrogel technology to other modalities such as gene therapy and products used to treat a wide variety of retinal diseases.”

Additionally, the current Senior Vice President of Clinical Development of Ocular Therapeutix, Rabia Gurses Ozden, MD, will become Chief Medical Officer July 1, and current Chief Medical Officer, Chair of Ophthalmology, Michael Goldstein, MD, will move into a part-time consulting role as a Senior Strategy Advisor.

“I am excited to expand our development capabilities with the addition of Dr. Kaiser as we advance our portfolio of innovative ophthalmic therapies for diseases of the front and back of the eye,” Antoine Mattessich, chairman and chief executive officer of Ocular Therapeutix, said in the statement. “Having someone of Dr. Kaiser’s caliber contributing to the great work we are already doing on retina programs is extremely exciting. His in-depth knowledge and experience should have an immediate impact as we finalize plans to move OTX-TKI into Phase 2 clinical development. We are developing this product candidate to set the standard of care for sustainability in the treatment of wet AMD. »

Aubrey L. Morgan